Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Sees Significant Increase in Short Interest

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the target of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 131,600 shares, a growth of 15.0% from the October 31st total of 114,400 shares. Currently, 0.8% of the company’s stock are short sold. Based on an average daily trading volume, of 36,100 shares, the days-to-cover ratio is presently 3.6 days.

Analysts Set New Price Targets

CYTH has been the subject of several analyst reports. Maxim Group reiterated a “hold” rating on shares of Cyclo Therapeutics in a report on Tuesday, August 27th. HC Wainwright reiterated a “neutral” rating and set a $0.95 target price (down previously from $3.00) on shares of Cyclo Therapeutics in a research note on Friday, August 23rd. Finally, Ascendiant Capital Markets dropped their target price on Cyclo Therapeutics from $2.60 to $0.95 and set a “buy” rating on the stock in a report on Monday, August 26th.

Cyclo Therapeutics Stock Down 11.1 %

Cyclo Therapeutics stock traded down $0.08 during mid-day trading on Friday, hitting $0.64. The company had a trading volume of 28,681 shares, compared to its average volume of 21,719. The stock has a market cap of $18.41 million, a price-to-earnings ratio of -0.71 and a beta of -0.38. Cyclo Therapeutics has a 1 year low of $0.59 and a 1 year high of $2.12. The business has a fifty day moving average of $0.73 and a 200 day moving average of $0.98.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.